Estimates Revisions MannKind Corporation

Stocks

Market Closed - Nasdaq 00:00:00 24/09/2026 +04			5-day change	1st Jan Change
3.340 ^USD	-4.30%		-5.92%	-41.09%

09-09	MannKind Corporation and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management	CI
09-09	MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	MANNKIND CORPORATION
	WUXI APPTEC CO., LTD.
	ARGENX SE
	INSMED INCORPORATED
	BIONTECH SE
	GENMAB A/S
	PHARMAESSENTIA CORPORATION
	EXELIXIS, INC.
	SUMMIT THERAPEUTICS INC.
	MADRIGAL PHARMACEUTICALS, INC.
	Average
	Weighted average by Cap.